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The Impact of Polybrominated Diphenyl Ether (BDE-47) Administration in Mice and its 
Implications in Non-alcoholic Fatty Liver Disease 
 
 
BDE-47 is a brominated flame-retardant widely found in the environment. It can 
be found in the air, soil, water, and many household products, such as cars, computers, 
and furniture. Previous studies have shown that BDE-47 can accumulate in body tissues 
after human exposure to the compound, including in the human liver. This accumulation 
over time may contribute to a higher risk of Non-alcoholic fatty liver disease (NAFLD), 
which is characterized by the accumulation of fat in liver cells that is not due to alcohol 
consumption. Over time, this can lead to hepatic steatosis, liver cirrhosis, and eventually 
liver cancer or failure.  
 
Preliminary studies in human hepatocytes (HepG2 cells) have displayed an 
increase in lipids, triglycerides, and modulated lipogenic gene expression after being 
treated with BDE-47, which suggests that BDE-47 has the ability to induce lipid 
accumulation in the liver. BDE-47 was then tested further in an animal study, in which it 
was hypothesized that administration of BDE-47 in mice fed either a normal or high fat 
diet would increase liver fat content. Adult male mice were fed BDE-47 through their 
diets (0.0003% in 10% kcal or 45% kcal high fat diets) over a period of 8 weeks. Food 
consumption and body weights were measured every 2-3 days. After 8 weeks, a necropsy 
was performed, in which mice livers were collected for further analysis. Liver lipid, 
triglyceride, and cholesterol contents were then quantified using UV spectrophotometry.         
 
Average mouse body weights were graphed, showing a steady increase in the 
body weights of each treatment group over the time period of 8 weeks. Percent body 
weight gain was also graphed, and showed a significant increase in high-fat diet over the 
low-fat diet control. The treatment group fed both high-fat diet and BDE-47 showed 
significant percent weight change compared to both the low- and high-fat diet controls. 
After liver fat content was analyzed and graphed, the mice treated with BDE-47 showed 
slightly lower hepatic lipid, triglyceride, and cholesterol content than the low- and high-
fat-treated control mice. It was therefore concluded that the results of the animal study 
were not consistent with the data from the preliminary studies in HepG2 cells, in which 
there was an increase in total lipids and triglycerides in the BDE-treated cells. While the 
cell model supported the hepatic steatosis and NAFLD fat accumulation hypotheses in 
human hepatocytes, the animal model data does not support this; further research should 
be done to determine its implications in NAFLD. The next steps include analyzing gene 
expression using protein and RNA isolation samples, to conclude whether the lipid data 
observed can be supported by changes in gene expression. 
  
  
